Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03253991
Other study ID # ET002J
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date November 17, 2014
Est. completion date February 2, 2023

Study information

Verified date April 2023
Source InSightec
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects The objective of this prospective, single-arm study is to test the efficacy of treatment using the ExAblate Transcranial System and to further demonstrate safety in medication-refractory tremor inpatients with essential tremor (ET). The Indications for Use claim for this system is as follows: Treatment of medication-refractory tremor in patients with essential tremor.


Description:

The objective of this prospective, multi-site, single-arm study is to test the efficacy of treatment using the ExAblate Transcranial System and to further demonstrate safety in medication-refractory tremor in subjects with essential tremor (ET). Safety: To evaluate the incidence and severity of adverse events (AE/AEs) associated with ExAblate Transcranial MRgFUS treatment of medication-refractory ET Effectiveness: To determine the effectiveness of the ExAblate Transcranial MRgFUS treatment of medication-refractory tremor (i.e. ET). Efficacy will be determined utilizing the Clinical Rating Scale for Tremor (CRST) in ET from examinations at baseline and 3-Months post-ExAblate treatment. • This study is designed as a prospective, multi-site, single-arm study. Assessments of primary efficacy endpoints will compare the three months after ExAblate treatment to Baseline measurements for clinical symptom relief. Safety of ExAblate in the treatment of ET will be collected for one year after ExAblate treatment. Relative Safety will be evaluated using a common description of Significant Clinical Complications for patients treated in this study. This study will be performed on the 3T MR scanners. The secondary endpoints of the study are as follows: 1. Quality life claims: Questionnaire for Essential Tremor (QUEST) outcome (upper extremity questions) at Months 3 change from Baseline 2. Durability (as measured by QUEST upper arm extremity questions) of the procedure as reflected by the efficacy data through change from baseline measures through Month 12 follow up 3. Subject daily functionalities: as measured by CRST Part-C (subscales)Month 12 as compared to Baseline.


Recruitment information / eligibility

Status Terminated
Enrollment 154
Est. completion date February 2, 2023
Est. primary completion date February 2, 2023
Accepts healthy volunteers No
Gender All
Age group 22 Years to 99 Years
Eligibility Inclusion Criteria - Men and women age 22 years or older - A diagnosis of ET as confirmed from clinical history and examination by a neurologist or neurosurgeon specialized in movement disorder - Have had an inadequate response to one or two oral doses of medication, per local standards. An inadequate medication trial is defined as a therapeutic dose of each medication and poor response to drug, or the development of side effects as the medication dose is titrated. - Able to communicate sensations during the ExAblate TcMRgFUS treatment Exclusion criteria: - Subjects with unstable cardiac status - Severe hypertension (diastolic BP > 100 on medication) - Subjects with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc. - Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or Magnevist) including advanced kidney disease - Patient with severely impaired renal function - History of abnormal bleeding and/or coagulopathy - History of immunocompromise including those who are HIV positive. - History of intracranial hemorrhage - Cerebrovascular disease (multiple CVA or CVA within 6 months) - Subjects with uncontrolled symptoms and signs of increased intracranial pressure (e.g., headache, nausea, vomiting, lethargy, papilledema). - Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment (can be up to 4 hrs of total table time.) - Are participating or have participated in another clinical trial in the last 30 days - Significant claustrophobia that cannot be managed with mild medication. - Presence of any other neurodegenerative disease such as Parkinson-plus syndromes suspected on neurological examination. - Presence of significant cognitive impairment - Subjects with life-threatening systemic disease - Subjects with a history of seizures within the past year - Subjects with presence or history of psychosis

Study Design


Related Conditions & MeSH terms


Intervention

Device:
MRgFUS treatment
ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects

Locations

Country Name City State
China Chinese PLA General Hospital Beijing Beijing
China Henan Provincial People's Hospital Zhengzhou Henan
Japan Sadamoto Hospital Ehime
Japan Shonan Fujisawa Tokushukai Hospital Fujisawa
Japan Hokkaido Ohno Memorial Hospital Hokkaido
Japan Hokuto Hokkaido
Japan Ohanishi Noerological Center Hyogo
Japan Kumagaya General Hospital Kumagaya
Japan Department of Neurosurgery, Osaka University Hospital Osaka
Japan Tokyo Women's Medical University Hospital Tokyo
Taiwan Chang Bing Show Chwan Memorial Hospital Chang Hua

Sponsors (1)

Lead Sponsor Collaborator
InSightec

Countries where clinical trial is conducted

China,  Japan,  Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety - Will be determined evaluating incidence and severity of device related complications from first treatment day visit through all follow ups. Relative Safety will be evaluated describing Significant Clinical Complications for patients treated. All AEs will be reported and categorized by investigators as definitely, probably, possibly, or unrelated to the device or procedure and categorized by treatment group / treatment arm. Relative Safety will be evaluated using a common description of Significant Clinical Complications for patients treated in this study. 1 year
Primary Effectiveness - Will be evaluated using the Clinical Rating Scale for Tremors (CRST) for ET subjects. Comparison will be performed from examinations at baseline and 3-Months post-ExAblate treatment. Assessments of efficacy endpoints will compare the three months after ExAblate treatment to Baseline measurements for clinical symptom relief. 5 Years
See also
  Status Clinical Trial Phase
Withdrawn NCT05381688 - VIM DBS Respiratory Modulation: N-of-1 Trial
Recruiting NCT05101161 - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes N/A
Completed NCT02277106 - Evaluate SAGE-547 in Participants With Essential Tremor Phase 2
Recruiting NCT05769933 - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Terminated NCT02894567 - Evaluation of Directional Recording and Stimulation Using spiderSTN N/A
Terminated NCT02678429 - Atlas Predicted DBS Settings in Essential Tremor N/A
Completed NCT02523807 - Tremor Monitoring Device N/A
Active, not recruiting NCT02255929 - Gamma Knife Radiosurgery for Treatment of Essential Tremor N/A
Completed NCT01223144 - Decision-making and Emotion Recognition in Essential Tremor N/A
Completed NCT00906412 - Ventrointermediate Nucleus (VIM DBS) and Working Memory N/A
Recruiting NCT05214222 - Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma Phase 2
Completed NCT03051178 - Wearable Sensor for Responsive DBS for ET N/A
Recruiting NCT03795935 - Relief From Side Effects: Clinical Use of Electrodes With Direction N/A
Not yet recruiting NCT06036368 - Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential Tremor N/A
Recruiting NCT05897775 - Coordinated Reset Deep Brain Stimulation for Essential Tremor Phase 1
Recruiting NCT05968976 - Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET N/A
Completed NCT06314139 - Tolerability and Efficacy of Continuous Theta-burst Stimulation for Essential Tremor: A Randomized Study. N/A
Recruiting NCT04501133 - Sensory-specific Peripheral Stimulation for Tremor Management N/A
Active, not recruiting NCT03560622 - Functional Neuroimaging Feedback for Focused Ultrasound Thalamotomy N/A
Completed NCT00368199 - Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes N/A